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Leishmaniasis is an endemic disease caused by the protozoan parasite
Leishmania. Current treatments for the parasite are limited by cost, availability, and
drug resistance as the worldwide occurrence of leishmaniasis continues to be more
prevalent. Sulfonamides are a class of compounds with medicinal properties that have
been used to treat bacterial and parasitic diseases via various pathways. In this study,
newly synthesized, unique structural analogs of sulfonamide compounds were
assessed for their impact on Leishmania cell viability and potential pathways for
inhibition were evaluated. Leishmania tarentolae (ATCC Strain 30143) axenic
promastigote cells were grown in BHI medium and treated with varying concentrations
of the unique sulfonamide compounds. Light microscopy and viability tests were used
to assess the cells with and without treatment. Recombinant Leishmania major
dihydrofolate reductase-thymidylate synthase (DHFR-TS) bifunctional enzyme was
expressed in E. coli, extracted, and purified. DNA sequencing at University of Illinois,
Urbana-Champaign (UIUC) confirmed the gene was expressed correctly, but the
recombinant protein did not exhibit catalytic activity. Future work should include
evaluation of the inhibitory effects of the sulfonamides on the recombinant DHFR-TS.

The conclusions of this work will help determine potential applications for tested
sulfonamides improving future medicinal therapies for this disease.
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CHAPTER I
INTRODUCTION
LEISHMANIASIS AND LEISHMANIA
Leishmaniasis is a disease caused by protozoan parasites of the genus
Leishmania. Leishmaniasis is transmitted by sandflies and is often found in areas of
Africa, Central and South America, the Mediterranean regions, Central and East Asia,
and Southeastern Europe The disease is endemic in over eighty countries worldwide
and is considered a dangerous public health concern with an incidence of 1.3 - 2 million
affected each year with approximately 310 million at risk of infection.1 The disease can
present in three main ways: cutaneous, mucocutaneous, or visceral leishmaniasis.2
Cutaneous leishmaniasis, the most common form, causes painful sores that may
start as papules or nodules and end as ulcers that may develop within a few weeks or
months after parasite transmission to the host. Species of Leishmania known to cause
cutaneous leishmaniasis include Leishmania tropica, L. major, L. aethiopica, L.
infantum, and L. donovani in the Old World (Eastern Hemisphere) and include the L.
mexicana species and the subgenus Viannia species in the New World (Americas).3
Mucocutaneous, or mucosal, leishmaniasis is a consequence of the Viannia
subgenus of Leishmania infecting the mucous membranes of the nose, mouth, or throat,
typically after years of cutaneous infection. This type of leishmaniasis can cause severe
physical damage to the infected areas.3
Visceral leishmaniasis is the most life threatening form of the disease, as it
affects internal organs such as the spleen, liver, and bone marrow. Hosts typically
develop the disease months to years after the initial infection, which can cause fever,
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swelling of the spleen and liver, and reduced red blood cell, white blood cell, and
platelet counts.4 Visceral leishmaniasis is usually caused by the L. donovani, L.
infantum or L. chagasi species.3
Studies have shown that Leishmania tarentolae, a species isolated from the
gecko Tarentolae annularis, is a suitable model for in vitro screening of anti-leishmanial
compounds. Because this form of Leishmania is not infectious to humans, the axenic
form of the parasite is considered suitable for preliminary potential anti-leishmanial
compound studies.5
Leishmania are digenic and can exist as two cell stages: amastigotes and
promastigotes. As can be seen in Figure 1,3 the promastigote stage of Leishmania is
transferred to an alternative host upon feeding by an infected sandfly.6 A macrophage
or other phagocytic cells in the immune system phagocytize the cells. Once in the
phagocytic cell, the Leishmania transform to the amastigote stage, which is
characterized by a more spherical shape and loss of flagellum. Amastigotes replicate in
the phagocytic cell until its rupture and the subsequent release of amastigotes thus can
lead to infection of other phagocytic cells. The amastigote stage of the Leishmania has
several characteristics different from the promastigote stage, including changes in gene
expression leading to enzymatic changes that allow the cells to survive in the acidic
environment of a phagocytic cell.7

2

Figure 1. Life cycle of Leishmania. Leishmania present as different cell stages within
their lifecycle, with different cell morphology and genes expressed (modified from
Centers for Disease Control and Prevention3).

The diversity in presentation of leishmaniasis owing to the many different species
of the parasite make it a difficult treatment target. In addition, the life cycle of the
parasite leads to changes in gene and enzyme expression in the different hosts,
presenting additional complexity in identifying and designing small molecules for
specific drug targets. With the disease affecting nearly 2 million people annually,
identifying new therapeutics has become more pertinent in preventing spread and
improving quality of life for those affected.
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CURRENT TREATMENTS FOR LEISHMANIASIS
Treatments exist today for the three types of leishmaniasis;2 however, due to the
infections primarily occurring in developing countries with weak infrastructure and
impoverished economies, access to these treatments is costly and complicated.
Advancement of known and new treatments is largely ignored and the World Health
Organization (WHO) has considered leishmaniasis a “neglected” disease.1 Common
treatments for leishmaniasis generate increasing concerns over variable responses in
different species of the infective parasite, as well as failure in treatment due to
resistance from overuse.
Pentavalent antimonial (SbV) drugs are typically the first line of defense for all
types of leishmaniasis infections, though studies have shown SbV drugs to have threeto fivefold greater sensitivity in L. donovani and L. brasilensis species compared to L.
major, L. tropica, and L. mexicana species.8 However, many scientists believe that
because of widespread overuse, the acquired resistance to the treatment has increased
and some species of the parasite have become refractory to the treatment.9
Amphotericin B, a polyene antibiotic, has been used in areas with SbV drug
resistance with some success. However, side effects are reported to be a concern. 10
Clinical resistance to amphotericin B is currently rare, but with the increasing use of the
treatment in place of antimonial drugs, it is expected that resistance could become an
issue.9 Resistant clones of L. donovani promastigotes have been identified in cell
cultures and have been seen to express mutations with changes in the sterol profile of
their plasma membrane.11
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The first oral agent approved for treatment of leishmaniasis is miltefosine, with
cure rates of 94% for visceral leishmaniasis12; however, the drug maintains
subtherapeutic levels due to its slow clearance in the host that may lead to greater
opportunity for drug resistance.13 Studies have shown variation in sensitivity of
amastigote and promastigote forms of different species of Leishmania to miltefosine,
with L. donovani being the most sensitive and L. major being the least.14
Other therapies are also available, but the opportunity for resistance in different
species of the parasite as a function of use and application is high.9 In 2010, the World
Health Organization identified high cost of medicines, treatment availability, lack of
updated protocols for application, and non-continuous supply of the most effective
treatments to be the largest hurdles for treatment of the disease in the most highly
impacted regions of the world.15 Availability of treatments with greater ease of use,
lower treatment rates, and less sensitivity to resistance would be of great benefit
globally.

SULFONAMIDES AND THEIR INHIBITORY EFFECTS
One possible treatment option for leishmanisis is the development of unique
sulfonamides that target parasite cell function and inhibit cell viability and proliferation
while causing minimal negative side effects for the host. Sulfonamide drugs are
characterized by the presence of a –S(=O)2-NH2 functional group in the compound.
Sulfonamides became popular antibacterial agents in the 1940s, though the first
sulfonamide drug, Prontosil (Figure 2) was first patented in 1932.16 The drug was
5

synthesized by Josef Klarer and Fritz Mietzsch and found effective against bacterial
infections in mice by Gerhard Domagk in 1932, and in 1939 Domagk was awarded the
Nobel Prize in Medicine for his work with the first medicine that could treat a range of
bacterial infections in humans.17 Sulfonamides, or sulfa drugs, are commonly used as
chemotherapeutic and preventative medicines for various diseases, with over 30 such
drugs being in clinical use as of 2014.18 Sulfa drugs have been used as
antihypertensive,19 antibacteria,l20 antiprotozoal,21 antifungal,22 and anti-inflammatory
agents.18 Sulfonamide derivatives have also been used to treat urinary, intestinal, and
ophthalmic infections, burns, ulcerative colitis,23 rheumatoid arthritis,24 and more
recently, cancer,25 Alzheimer’s disease,26 and HIV.27

Figure 2. Chemical structure of Prontosil.16
Potential side effects of sulfa drugs include skin rash, itching, headache,
dizziness, diarrhea, tiredness, nausea or vomiting, pale skin, joint pain, and sensitivity to
light, and allergies to sulfonamides and other sulfa drugs are common.28 The side
effects of anti-leishmanial SbV drugs often include nausea and vomiting, joint pain,
hepatitis, pancreatitis and cardiac dysrhythmias and require frequent monitoring for
6

toxicity.29 Clinical studies with amphotericin B have shown infusion reactions and renal
impairment while miltefosine, in the active oral form, has some reproductive toxicity as
well as gastrointestinal side effects, which can cause nausea and vomiting.29 Severity
of side effects are dependent on treatment concentrations and accumulation in patients.
Though sulfonamides have been seen to form renal crystals, this can be managed by
monitoring treatment concentrations and could potentially be reduced by improving
water solubility.30
Studies have identified the primary pathway of sulfonamide inhibition as
competitive inhibitors of the enzymes dihydropteroate synthase (EC 2.5.1.15) and
dihydrofolate reductase (EC 1.5.1.3; DHFR), enzymes involved in folate metabolism.31
Folate synthesis and the products of the folate pathway are important in the synthesis of
purines and DNA. This pathway of inhibition is also a primary method of treatment of
cancers using sulfonamide drugs,32 as it prevents the replication of DNA and cell
proliferation. Other modes of inhibition induce disruption of microtubule activity, thereby
decreasing cell division.33 Studies have also shown that the inhibition of DHFR can
allow for an accumulation of NADPH, which would have an inhibitory effect on glucose6-phosphate dehydrogenase in the oxidative phase of the pentose phosphate
pathway.34 The pentose phosphate pathway has two primary functions: regeneration of
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) for use in
multiple pathways and generation of pentoses, which are necessary for nucleic acid
synthesis.35
Sulfonamides are typically prepared by reacting a sulfonyl chloride compound
containing the desired side chain with ammonia or an amine containing the second
7

desired side chain, making the process fairly simple and low cost.18 Due to the stability
of these compounds, if stored properly, they can have a shelf life of approximately two
years.36 Sulfa drugs can be applied orally, topically, or intravenously,37 allowing them to
be good treatments for all three types of leishmaniasis.

FOLIC ACID METABOLIC PATHWAYS
As shown in Figure 3, the various intermediary metabolites of folate have a
variety of roles, as cofactors, in a variety of pathways, especially in one-carbon
transfers.38 Thus, amino acid metabolism, choline derivatives (such as
phosphatidylcholine formation from phosphatidylethanolamine), as well as nucleic acid
metabolism can be affected as folic acid metabolism is affected.39
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Figure 3. The folate metabolic pathway.39

Sulfonamides have been used to treat bacteria and Leishmania species perhaps
by mainly inhibiting the enzymes dihydropteroate synthetase (DPS) and dihydrofolate
reductase (DHFR).7 These enzymes are essential in the production and metabolism of
folate, affecting the synthesis of DNA. DHFR, specifically, allows for the reduction of
7,8-dihydrofolate (H2F) to 5,6,7,8-tetrahydrofolate (H4F) while oxidizing the NADPH to
NADP+ (Figure 4).40
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Figure 4. Reaction catalyzed by DHFR. Dihydrofolic acid (H2F) is reduced to
tetrahydrofolic acid (H4F) with the oxidation of NADPH to NADP+.40

The proposed mechanism for the DHFR enzyme, from Mycobacterium
tuberculosis, is shown in Figure 5.41 The primary coordinating amino acid of the
dihydrofolate binding pocket is an aspartate or glutamate, dependent on species, as the
carboxyl group of the amino acid is important in hydrogen bonding to the pterin ring of
the dihydrofolate. Water is also necessary to ensure a proton transfer occurs along with
the hydride transfer from NADPH, allowing for the final product of tetrahydrofolate (H4F).
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Figure 5. Proposed catalytic mechanism by DHFR from Mycobacterium tuberculosis.41

DHFR activity is the major endogenous source for H4F, and is important in
maintaining the cellular pools of H4F and its derivatives for the synthesis of purines and
thymidylate among other highly important products. Without DHFR, cells are unable to
grow and proliferate without addition of exogenous H4F.40 Because of this, DHFR is a
primary target for treatment against rapidly growing cells, such as bacteria, parasites,
and even cancers.
It is important to note, however, that Leishmania have a more complex pathway
of folate metabolism than bacteria. Leishmania contain a bifunctional polypeptide form
11

of DHFR that also encodes thymidylate synthase (EC 2.1.1.45) (TS), meaning the
enzyme, DHFR-TS, is reversible in the presence of N5, N10 – methylene tetrahydrofolate
(CH2=H4F) and deoxyuridine monophosphate (dUMP). Although the TS enzyme is
present ubiquitously among cells, it is typically only found in the bifunctional form in
protozoa and plants.42 In addition, a second enzyme, pteridine reductase 1 (EC
1.5.1.33) (PTR1), has been identified to reduce folates and unconjugated pteridines in
the folate pathway, as seen in Figure 6.43 PTR1 can act as a metabolic bypass of
DHFR inhibition drugs solely targeting tetrahydrofolate production by the bifunctional
DHFR-TS enzyme and halting single carbon metabolic pathways.44
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Figure 6. The folic acid metabolic pathway for Leishmania. The proposed metabolic
pathway for folate and biopterin in Leishmania, showing PTR1 can catalyze both the
reduction of folate and dihydrofolate (H2F) to tetrahydrofolate (H4F), which are essential
steps in the synthesis of DNA.43

PTR1 plays an important role in the salvage and oxidation of pterins.44 Studies
have shown that DHFR-TS has no role in the reduction of pterines, but PTR1 can have
significant activity with folates, increasing the opportunity for DHFR drug target
resistance in Leishmania.44 Though the role of biopterin in trypanosomatids is not well
established, PTR1 and quinoid dihydropteridine reductase (qDPR) have been identified
as important for recycling quinonoid dihydrobiopterin (Figure 7).44 This recycling may
also have an important role in the biosynthesis of tyrosine for these parasites (Figure 7).
Studies have also shown that mutants lacking PTR1 are unable to survive, even in the
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presence of folate or dihydrofolate45 and, therefore, play an important role in
Leishmania growth and viability. Because of this additional enzyme complexity,
determining the pathways of inhibition of specific treatments is important in determining
the efficacy of a drug and likelihood for species resistance.

Figure 7. Metabolic pathway of biopterin in L. major.46

In this thesis, newly synthesized, unique sulfonamide compounds were assessed
for their impact on Leishmania tarentolae cell viability and potential pathways of
inhibition were investigated. Due to the known inhibitory effects of sulfonamides on
DHFR, the folate pathway was a focus of interest. Axenic promastigotes (ATCC Strain
14

30143) were grown in brain heart infusion (BHI) medium and treated with varying
concentrations of the synthesized sulfonamides. Light microscopy and viability tests
were used to assess the cells with and without treatment. The folic acid pathway was
probed by adding folic acid to the cells and evaluating the effects with and without
treatment. Recombinant DHFR-TS from L. major was expressed in E. coli, extracted,
and purified. Enzyme activity was evaluated by measuring the oxidation of NADPH to
NADP+ using change in absorbance at 340 nm.47 However, catalytic activity was not
exhibited by the enzyme and additional work is needed to evaluate the effects of the
unique inhibitory sulfonamides on DHFR-TS from Leishmania. Understanding the form
and inhibitory function of these sulfonamide compounds would be helpful in developing
treatments for Leishmania that may overcome the many complexities of their infective
capability.
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CHAPTER II
MATERIALS AND METHODOLOGY
PROMASTIGOTES
Leishmania tarentolae promastigotes (ATCC Strain 30143, American Type
Culture Collection) were grown in sterile conditions in brain heart infusion (BHI) medium
supplemented with penicillin and streptomycin (100 units and 0.1 mg per mL
respectively) and hemin (10 µM) in flasks (Falcon, polystyrene) following the method of
Morgenthaler et al.48 Promastigote forms of the Leishmania cells were transferred
during the log phase of the growth curve to maintain cell cultures. Work with
promastigotes was performed in a sterile hood to prevent contamination.

MTT ASSAY

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
was used to evaluate promastigote viability at different points in the growth curve and
after treatments. The MTT assay is a colorimetric assay which assesses cell viability
based on the activity of oxidoreductase enzymes.49 These enzymes reduce the yellow
tetrazolium reagent to an insoluble, purple formazan. One hundred microliters of cells
were transferred to wells of a 96 well plate (Fisher, polypropylene), 4 replicates to allow
for calculation of mean and standard deviation, then 10 µL of MTT reagent (Sigma, 5
mg per 1 mL water) was added to each well with gentle mixing. Cells and reagent were
allowed to incubate for 1 hour before the addition of the stopping agent which consists
of 10% Triton X-100 (v/v), 225 mL isopropanol, and 2 mL 0.14 M hydrochloric acid. A
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96 well plate reader spectrophotometer (BIO RAD, iMark Microplate Reader) was then
used to obtain absorbance data at 595 nm. BHI medium, without cells, treated with
dimethyl sulfoxide (DMSO) or the same concentration of sulfonamide in DMSO being
tested were used as blanks as appropriate. Corrected absorbance at 595 nm is then
assumed to correlate with the amount of viable cells present.

MICROSCOPY

Light microscopy (JENCO, Model CP-2A1) was used to qualitatively assess cells
for shape, clumping, and cell motility. Cells were evaluated in the flasks, without
fixation, since this is an inverted microscope. Pictures and videos were obtained with a
Kodak EasyShare C743 camera.

SULFONAMIDE SYNTHESIS AND CHARACTERIZATION

Starting materials were obtained from commercial sources and used as received.
Dr. Hamaker synthesized N-(2’-methylthiophenyl)-1-napthalene sulfonamide
(Compound A), N-(2’-methoxyphenyl)-1-napthalene sulfonamide (Compound B), and N(2’-methylphenyl)-1-napthalene sulfonamide (Compound C) by reaction of 1naphthalene sulfonyl chloride with the appropriate aniline in pyridine. A 500 MHz NMR
was used to acquire 1H spectra for samples in DMSO-d6. The generic reaction is
shown in Figure 8.50
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Figure 8. Generic reaction to synthesize sulfonamides. Sulfonamides A, B, and C
were synthesized when 1-napthalene sulfonyl chloride was mixed with the appropriate
aniline in pyridine.

To synthesize N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide
(Compound D), 30 mL of aqueous 1 M sodium carbonate containing 2.200 g (9.710
mmol) of 1-napthalenesulfonyl chloride and 1.528 g (10.11 mmol) 3-methyl-4aminobenzoic acid was prepared in a 250 mL Erlenmeyer flask. The solution was
allowed to stir for 24 hours and then acidified with 6 M hydrochloric acid. The
precipitate was filtered and washed with water. The precipitate that formed was
collected by vacuum filtration, washed with water, and air dried overnight to yield 1.765
g (47.33%) of Compound D as a light pink solid. 1H NMR (500 MHz, (CD3)2SO): 12.73
(br s, 1H, COOH); 10.16 (s, 1H, NH); 8.73 (d, 1H, aromatic); 8.23 (d, 1H, aromatic);
8.09 (m, 2H, aromatic); 7.69 (m, 2H, aromatic); 7.59 (m, 3H, aromatic); 7.20 (d, 1H,
aromatic); 1.95 (s, 3H, -CH3) (Appendix A).50
To synthesize N-(4-carboxyl)-1-naphthalene sulfonamide (Compound E), 25 mL
of aqueous 1 M sodium carbonate in a 125 mL Erlenmeyer flask was charged with
1.371g (10.00 mmol) of anthranilic acid and 2.269 g (10.01 mmol)
1-naphthalenesulfonyl chloride. The solution was stirred for 20 hours and acidified with
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6 M hydrochloric acid. The precipitate that formed was collected by vacuum filtration,
washed with water, and air dried overnight to yield 2.588 g (74.01%) of Compound E as
a white solid. 1H NMR (500 MHz, (CD3)2SO): 13.90 (br s, 1H, COOH); 8.62 (d, 1H,
aromatic); 8.31 (d, 1H, aromatic); 8.19 (d, 1H, aromatic); 8.04 (d, 1H, aromatic); 7.79 (d,
1H, aromatic); 7.69 (t, 1H, aromatic); 7.63 (m, 2H, aromatic); 7.34 (m, 2H, aromatic);
6.88 (t, 1H, aromatic) (Appendix B).50

EVALUATION OF SULFONAMIDE TREATMENT OF PROMASTIGOTES

The sulfonamides were dissolved in DMSO and added to promastigotes grown in
BHI medium. A large volume (60 mL) of cells were grown in a single flask (Falcon, 75
cm2 polystyrene) and transferred to smaller flasks, 5 mL (Falcon, 12.5 cm2 polystyrene)
or 10 mL (Falcon, 25 cm2 polystyrene) for treatment. This was done in an effort to
reduce variation in number and age of cells in each test flask. Promastigotes were
treated with varying concentrations of the sulfonamides (between 10 µM and 100 µM)
dissolved in DMSO, ensuring cells were exposed to no more than 1% (v/v) DMSO, at
different points in the growth curve for the cells (Figure 9). Untreated cells and cells
treated only with the same final volume DMSO were used as controls for these studies.
Blank samples were used to calculate the corrected average absorbance of the cellular
samples by subtracting the absorbance values of the blanks from the cellular values.
MTT assays were used to quantitatively evaluate cell viability, while light microscopy
was used to qualitatively assess cells for shape, clumping and cell motility. Each
experiment was performed in four wells in at least three experiments to confirm
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repeatability and a statistical Students t-test was used to determine statistical
significance for the results (p < 0.05 was considered significantly different). Cultures
determined to be severely inhibited were transferred to fresh medium to determine if
they were in early or late senescence phase and could recover. Those without recovery
(measurable MTT response) over 3 days were considered fully inhibited (dead).

Corrected Average Absorbance as a Function of Time
for Leishmania tarentolae Cells with 1% DMSO
Corrected Averaeg Absorbance at 595nm
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0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10

Lag
Phase
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Figure 9. Typical growth curve for Leishmania tarentolae promastigotes. The graph
shows the typical growth curve and phases for Leishmania tarentolae promastigotes,
where absorbance at 595 nm is representative of cell viability as a function of day in
culture. Each point is a mean ± standard deviation of n = 4.
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Cells shape, motility, and clumping were assessed with inverted light microscopy
daily. The results were documented subjectively and photography or video were used
as necessary for further documentation.

POTENTIAL PATHWAY OF INHIBITION INVESTIGATION

Potential pathway of inhibition in the presence of those sulfonamides with effects
on cell viability was evaluated by adding folate to the medium in concert with the
sulfonamide addition. If the pathway of inhibition is related to the folic acid metabolic
pathway, the cells should have improved viability when folate is added in the presence
of the sulfonamide. If folate does not protect the cells there is likely a different
pathway(s) of inhibition.
Cells were grown in the same manner as described above. Promastigotes were
treated with the most effective concentration of the sulfonamides shown to have a
negative effect on cell viability (100 µM) and the same concentration of folate. Both
were dissolved in the same vial of DMSO, and cells were treated with the combination,
ensuring cells were exposed to no more than 1% (v/v) DMSO, in the log phase of cell
growth. Untreated cells, cells treated only with 1% volume DMSO, cells treated with
100 µM folate, and cells treated with 100 µM sulfonamide were used as variables for
these studies. MTT assays were used to quantitatively evaluate cell viability, while light
microscopy (JENCO, Model CP-2A1) was used to qualitatively assess cells for shape,
clumping and cell motility. Each experiment was performed at least three times to
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confirm repeatability and a statistical Students t-test was used to determine statistical
significance for the results (p < 0.05 was considered significantly different). Cultures
determined to be severely inhibited were transferred to fresh medium to determine if
they were in early or late senescence phase and could recover. Those without recovery
(measurable MTT response) over 3 days were considered fully inhibited (dead).

DNA AMPLIFICATION BY PCR
To evaluate the enzyme DHFR-TS from L. major, the gene encoding DHFR-TS
was cloned using polymerase chain reaction (PCR) DNA amplification and the encoded
protein was expressed in E. coli cells. Leishmania major was chosen for this work, as it
is one of the human infective forms of the parasite, so studies related to therapeutic
inhibition of DHFR-TS would be applicable to a medically relevant form of the parasite.
Also, the genome for this species has been sequenced (Genbank ID: M12734).51
Standard methods used were adapted from Sambrook and Russell, Molecular Cloning –
A Laboratory Manual.52
Single-stranded DNA primers (Sigma) complementary to the 5’- and 3’- ends of
the gene were designed to amplify the gene encoding L. major DHFR-TS (Genbank ID:
M12734). When the primers are present in solution with genomic DNA from L. major,
the primers hydrogen bond with the complementary DNA of the gene of interest. PCR
(MJ Research, PTC-200 Peltier Thermal Cycler) was used to amplify the gene of
interest between the primers. After incubation at 94°C for 5 minutes, the PCR
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amplification, using the PCR Master Mix (Promega), involved the following program:
94°C for 15 seconds, 50°C for 30 seconds, and 72°C for 1 minute; 30 complete cycles
were performed. At 94°C the double stranded DNA template, from L. major, denatures
to form single strands of DNA to which the primers anneal at 50°C. This is then heated
to 72°C, where the OneTaq DNA polymerase (New England BioLabs, 2x concentration)
elongates the primers from the 5’-3’ direction. The volumes of materials used in the
PCR amplification are shown in Table 1. Deoxy ribonucleotide (present in the PCR
MasterMix, Promega, 2x concentration) addition occurs on both strands, and after 30
cycles 230 DNA strands, in theory, were synthesized.

Nuclease Free
(Autoclaved)
Water
22 µL
20 µL

PCR MasterMix
(Promega, 2x)
25 µL
25 µL

5' Oligonucleotide 3' Oligonucleotide
(Sigma, 100 µM) (Sigma, 100 µM)
1 µL
1 µL
1 µL
1 µL

Template
L. major
Genomic DNA
1 µL
1 µL

Magnesium Sulfate
(New England
BioLabs, 50 mM)
0
2 µL

Table 1. Materials and volumes used for PCR amplification of the DHFR-TS gene.

The primers were designed to include start and stop codons for the gene, the
appropriate nucleotide sequence to code for restriction enzyme target regions for
BamHI and HindIII, and 17 nucleotides of the 5’- sequence of the DHFR-TS gene, and
22 nucleotides of the 3’- sequence of the DHFR-TS gene, as seen in Figure 10. The
primers were ordered from Sigma-Aldrich.
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Figure 10. Primer sequences designed for PCR amplification of the L. major DHFR-TS
gene. The BamHI restriction enzyme sequence (GGATCC) is underlined in the 5’strand of the primer, and the HindIII restriction enzyme sequence (AAGCTT) is
underlined in the 3’- strand. The start codon, ATG, and stop codon, CTA, are shown in
bold, and the nucleotides of the gene are in the boxed region.

Agarose gel (1.4% (w/v)) electrophoresis was used to analyze the amplified
DNA. The gel was prepared by adding 1.4 g agarose (ISC BioExpress, GenePure LE
Quick Dissolve Agarose) to 100 mL 0.5x TBE Buffer (44.5 mM Tris base, 44.5 mM boric
acid, and 1 mM EDTA, purchased from Fisher) and microwaving until dissolved. After
cooling to approximately 50°C, 3 µL SYBR safe (Invitrogen) was added as an
intercalating fluorescent dye for visualization of DNA under UV light. The mixture was
poured into an agarose gel mold.
The PCR material was purified using a PCR purification kit (PureLinkTM Quick
PCR Purification Kit, InvitrogenTM). The PCR samples and pET-45b plasmid were
digested with BamHI (New England BioLabs, 20,000 U/mL) and HindIII (New England
BioLabs, 20,000 U/mL ) enzymes for 4 hours using volumes shown in Table 2. The
pET-45b plasmid encodes a six histidine tag (His-tag) within the reading frame for the
inserted gene; therefore, the expressed protein should contain a His-tag that can be
used for protein purification on a cobalt or nickel resin column. The plasmid also
encodes a gene for ampicillin resistance.
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PCR sample
pET-45b

PCR
Material
16 µL
0 µL

pET-45b
Plasmid
0 µL
5 µL

SmartCut Buffer
Nuclease Free (New England BioLabs,
Water
10x concentration)
0 µL
2 µL
11 µL
2 µL

BamHI
Restriction
Enzyme
1 µL
1 µL

HindIII
Restriction
Enzyme
1 µL
1 µL

Table 2. Respective volumes for DNA digestion of PCR products and plasmid.

To 15 µL of sample from the restriction enzyme digestion, 5 µL Blue/Orange
Loading Dye (Promega, 6x) was added. A standard 1 kilo-base pair (Kb) ladder
(Promega) was used as a molecular weight standard for comparison (Figure 11). Five
µL of the standard and 15 µL of sample were loaded onto separate lanes of the gel.
Then 150 voltage was applied for approximately 45 minutes. Results were visualized
using a fluorescent gel imaging system (Kodak, Gel Logic 200 Imaging System) and
imaging software (Kodak ID 3.6).
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Figure 11. Promega 1 Kb Ladder standard in 0.7% agarose gel.53

RECOMBINANT GENE LIGATION

To improve the likelihood of a successful ligation, DNA with the expected number
of base pairs (approximately 1500 base pairs) for the DHFR-TS gene and pET-45b
plasmid were cut directly from the gel and purified using a DNA purification kit (DNA
Purification System, Promega). Ligation of the amplified DNA and the pET-45b plasmid
was performed with different volumes of plasmid and PCR material, as shown in Table
3. The materials were incubated at 15°C for approximately 24 hours.
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DHFR-TS 1
DHFR-TS 2
Control - No DHFR-TS

pET-45b
Plasmid
1 µL
4 µL
1 µL

PCR
material
8 µL
4 µL
0 µL

T4 DNA Ligase Buffer
(New England BioLabs,
10x concentration)
1 µL
1 µl
1 µL

T4 DNA Ligase
(New England BioLabs, Nuclease Free
400,000 U/mL)
Water
0.5 µL
0 µL
0.5 µL
0 µL
0.5 µL
8 µL

Table 3. Ligation mixture volumes for DHFR-TS gene with pET-45b plasmid. The
ligation was performed with two different volumes of pET-45b plasmid and PCR material
as the optimal amount of each needed for ligation was unknown. The sample labeled
DHFR-TS 1 contained 8 µL PCR material, while the sample labeled DHFR-TS 2
contained 4 µL PCR material.

DNA TRANSFORMATION IN E. COLI

Once the ligation was complete, the DHFR-TS gene should have been inserted
into the plasmid (referred to as ligation mixture). To transform E. coli to express the
gene to be used for protein expression, 50 µL of methyltransferase deficient, chemically
competent E. coli cells suitable for replication of a plasmid free of Dam and Dcm
methylation (dam-, dcm- E. coli cells; New England BioLabs) were added to a 14 mL
polystyrene test tube with a lid (Fisher Brand, Fisher). Five µL of the ligation mixture
(DHFR-TS 1, DHFR-TS 2, or Control – No DHFR-TS from Table 3) was added and
incubated on ice for 30 min, placed in a 42°C water bath for 30 sec, and placed back on
ice for 2 min. One mL of Lysogeny Broth (LB) medium (GeneMate, LB Miller Broth
Powder) was added and the mixture was incubated with agitation (225 rpm) at 37°C for
30 min. The cells were centrifuged (Force Micro, Force1618) for 1 min, 10,000 rpm
(8,944x g) in a microcentrifuge (Fisher Brand, 1.5 mL polypropylene) tube to pellet the
cells, which were re-suspended in a minimal volume (50-100 µL) of LB medium. The
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suspension was dispersed onto an LB agar plate containing 100 µg/mL ampicillin and
the cells were allowed to grow overnight at 37°C while shaking at 225 rpm. Colonies
that grew were assumed to contain the ampicillin resistance provided by retaining the
pET-45b plasmid containing the DHFR-TS gene.

To grow large amounts of the cells that should contain the plasmid, a single
colony of cells was removed and added to 2 mL of LB medium in a polystyrene test tube
(Fisher Brand, Fisher) with lid containing 100 µg/mL ampicillin per 1 mL of LB medium.
These were allowed to grow overnight at 37°C with 225 rpm agitation. The DNA from
these cells was purified using the Wizard Plus SV Miniprep DNA Preparation System kit
(Promega).

A digestion, as described above (Table 2) using BamHI and HindIII restriction
enzymes, was performed on the purified DNA and agarose gel electrophoresis was
used to confirm the plasmid contained a DHFR-TS gene. The DHFR-TS gene consists
of approximately 1500 base pairs.

PROTEIN EXPRESSION IN E. COLI

For protein expression, 1 µL of purified plasmid DNA containing the DHFR-TS
gene was added to 50 µL of rare codon isoleucine, proline, leucine (RIPL) E. coli cells
(Agilent Technologies), and the DNA transformation procedure, as previously
discussed, was used to transform the plasmid into the RIPL E. coli. RIPL E. coli cells
are often necessary for expression of genes that contain rare codons for isoleucine,
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proline, and leucine that are more common in non-E. coli species. The cells were
allowed to grow for 1 hour at 37°C with agitation (225 rpm) and were dispersed onto an
agarose plate containing 100 µg/mL ampicillin (AMP) and 34 µg/mL chloramphenicol
(CM). The agarose plate was incubated at 37°C overnight. Any colonies that grew
were assumed to contain the plasmid with the DHFR-TS gene insertion.

A single colony was removed from the plate and placed in 5 mL of LB media
containing 100 µg/mL AMP and 34 µg/mL CM. After 24 hours of growth at 37°C and
225 rpm agitation, these cells were transferred to 50 mL LB containing 100 µg/mL AMP
and 34 µg/mL CM and allowed to grow for 3 hours at 37°C, 225 rpm. Finally, the 50 mL
cell growth was transferred to 1200 mL LB media containing 100 µg/mL AMP and 34
µg/mL CM and grown at 37°C, 225 rpm for 24 hours. A 1 mL sample was removed for
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. To
the rest of the cells, 0.0500 g of isopropyl β-D-1-thiogalactopyranoside (IPTG) was
added for a final concentration of 0.175 mM. After 3 hours of growth, the cells were
pelleted in 250 mL aliquots by centrifugation (5000x g for 5 min, Beckman, Avanti
J-25 I). Cells were re-suspended in 50 mM Tris, 100 mM NaCl pH 7.5 buffer as 20 mL
aliquots and stored/frozen in 50 mL conical tubes (Corning, polypropylene centrifuge
tubes).

PROTEIN EXTRACTION AND PURIFICATION

To harvest the recombinant protein, the frozen cell pellet was placed on ice to
thaw and 500 µL protease inhibitor cocktail (Sigma) was added. The protease inhibitor
cocktail consists of 2 mM 4-(2-Aminoethyl)benzensulfonyl fluoride hydrochloride
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(AEBSF), 0.3 µM Aprotinin, 116 µM Bestatin, 14 µM E-64, 1 µM Leupeptin, and 1 mM
EDTA54, all of which inhibit different classes of proteases. A French Pressure Cell
Press (Spectronic Instruments, SLM-AMINCO) was used to lyse the cells at 10,000 psi
to release soluble proteins. The lysed material (crude extract) was collected and
centrifuged at 31,000x g for 20 min at 4°C. A sample of the pre-centrifuged material
and a sample of the supernatant were saved for SDS-PAGE analysis. The supernatant
was collected for protein purification and the pellet was saved for protein analysis.
An affinity column was prepared using TALON® metal affinity resin, a cobalt
containing resin. Approximately 3 mL of resin was added to a column and equilibrated
with approximately 45 mL of Tris buffer (50 mM Trizma, 150 mM NaCl, pH 7.5). The
supernatant was applied to the column and material that passed through the column
was collected (column flow-through). Because of the His-tag present on the amino
terminal of the recombinant protein, it was expected that any expressed DHFR-TS
protein would bind to the cobalt column due to Lewis acid-Lewis base interactions. The
column was washed with approximately 45 mL Tris buffer, to remove non-adhered
protein in the column, and this was collected. Approximately 20 mL of Tris buffer
containing 10 mM imidazole was added to the column to remove (wash) any loosely
bound protein by competitive binding of imidazole to the resin; the wash was collected.
Finally, 10 mL of Tris buffer containing150 mM imidazole was added, and 1 mL fractions
were collected in microcentrifuge tubes. The 150 mM imidazole buffer was expected to
remove any DHFR-TS tightly bound to the resin by the His-tag.
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BIO-RAD ASSAY FOR PROTEIN CONCENTRATION DETERMINATION

The Bio-Rad reagent (Bio-Rad) was used for protein concentration determination
in each fraction collected. The Bio-Rad Protein Assay causes a shift in absorbance
from 465 nm to 595 nm when the reagent-dye is bound to protein.55 A standard protein
curve was developed using known concentrations of bovine serum albumin (BSA) and
absorbance was measured at 595 nm. The following table (Table 4) was used to
develop the standard protein curve (provided by J. Walker, Jan., 2015), while Figure 12
shows the standard curve and linear equation.

Tube

Volume of 0.1
mg/mL BSA

1
2
3
4
5
6
7

0 µL
20 µL
40 µL
80 µL
120 µL
160 µL
200 µL

H2O
800 µL
780 µL
760 µL
720 µL
680 µL
640 µL
600 µL

Bio-Rad Reagent
(Bio-Rad, Bio-Rad Protein Assay Dye
Reagent Concentrate)

Protein
Amount (µg)

Absorbance at
595 nm

200 µL
200 µL
200 µL
200 µL
200 µL
200 µL
200 µL

0
2
4
8
12
16
20

0.002
0.133
0.134
0.344
0.540
0.634
0.776

Table 4. Data for standard BSA protein curve provided by J. Walker.
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Absorbance at 595 nm as a Function of Protein Added
0.900
0.800

y = 0.0388x + 0.0224
R² = 0.987
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Figure 12. Standard protein curve for protein concentration determination.

Table 5 shows the volumes from each fraction used for protein determination.
The absorbance was then measured at 595 nm using visible spectroscopy (Hewlett
Packard, 8453 UV-Vis Spectrometer). Protein concentration was determined based on
a standard absorbance as a function of concentration of bovine serum albumin (BSA)
curve with the line equation y = 0.0388x + 0.0224, where “y” is absorbance at 595 nm
and “x” is the apparent protein mass (µg). Protein concentration was calculated by
dividing the amount of protein by the volume used in the assay.
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BioRad Reagent
(Bio-Rad, Bio-Rad Protein Assay
Dye Reagent Concentrate)

Sample:
Blank
Crude Extract
Supernatant
Column Flow-Through
Buffer Wash
10mM Imidazole
150 mM Imidazole Fraction

200 µL
200 µL
200 µL
200 µL
200 µL
200 µL
200 µL

H2O
800 µL
798 µL
798 µL
790 µL
700 µL
700 µL
750 µL

Protein
Sample
0 µL
2 µL
2 µL
10 µL
100 µL
100 µL
50 µL

Table 5. Volumes of reagents used for Bio-Rad protein assay. Per the product
information from Sigma-Aldrich, solutions containing less than 200 mM imidazole and
2.0 M Tris do not interfere with absorbance at 595 nm.56

SDS-PAGE PROTEIN ANALYSIS

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was
used to evaluate samples for protein expression using the general method of
Laemmli.57 DHFR-TS was expected to have a molecular weight of approximately 60
kilo-Daltons (kDa). Using gel electrophoresis, proteins in a sample can be separated
based on apparent molecular weight.
SDS running gels were prepared by mixing 2.15 mL deionized (DI) water, 1.5 mL
40% acrylamide (Sigma), 1.75 mL 1.5 M Tris pH 8.8 buffer, 0.05 mL 10% (w/v) SDS,
10% (w/v) freshly made ammonium persulfate (APS), and 2 µL
tetramethylethylenediamine (TEMED) (Sigma). This mix was quickly pipetted between
the glass plates of an SDS-PAGE mold apparatus (Bio-Rad, Mini PROTEAN® System
Glass Plates) as the protein resolving gel. Isopropanol was added to create a level
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interface for the stacking gel portion. Once the protein resolving gel polymerized, the
isopropanol was removed and the stacking gel, consisting of 1.5 mL DI water, 0.25 mL
40% acrylamide, 0.25 mL 1 M Tris pH 6.8 buffer, 0.02 mL 10% SDS, 20 µL APS, and 2
µL TEMED, was added and the well comb was inserted. SDS gels were typically made
in batches of 2-4 and were stored in 1x SDS-buffer solution at 5°C for later use.

SDS-PAGE protein samples were prepared with no more than 15 µg of protein
for non-purified samples and no more than 2.5 µg of protein for purified samples to be
loaded on the gel. The appropriate volume of protein solution and 4 µL 4x SDS dye
were combined, with Nanopure water being added to a final volume of 20 µL. Pellet
samples were resuspended in 20 µL 1x SDS dye. The samples were boiled for 5 min to
denature the proteins before loading. Precision Kaleidoscope Standard (Bio-Rad,
Precision Plus ProteinTM KaleidsocopeTM Prestained Protein Standards; 5 µL) was used
to evaluate protein molecular weights (Figure 13). The 1x SDS-PAGE Running Buffer
(25 mM Trizma, 250 mM glycine, 0.1% (w/v) SDS, pH 8.3) was added to the SDSPAGE chamber. Then, 150 V was applied and the current was allowed to pass through
the gel until the blue dye front ran off the gel. Coomassie blue stain was used to
visualize the protein bands, and de-stain, composed of 45% methanol, 10% acetic acid,
and 45% water (v/v/v), was applied to remove stain from regions of the gel devoid of
proteins. Gels were preserved by lamination as necessary.
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Figure 13. Precision Plus ProteinTM KaleidsocopeTM Prestained Protein Standards.58

DHFR ENZYME ACTIVITY ASSAY

In a UV transparent cuvette, purified L. major DHFR-TS protein was incubated
with 400 µM final concentration NADPH (Sigma) in pH 6.5 Tris, 150 mM imidazole
buffer at room temperature, after blanking with pH 6.5 Tris, 150 mM imidazole buffer.
After approximately 5 min of incubation, 50 µM final concentration dihydrofolic acid was
added. Absorbance was measured at 340 nm utilizing the kinetic mode (Hewlett
Packard 8453 UV-Vis spectrophotometer, HP 8453A software). Because NADPH
absorbs at 340 nm, if the DHFR-TS enzyme is active, a reduction in absorbance at that

35

wavelength would be expected with the oxidation of NADPH to NADP+ in a
stoichiometric reduction of dihydrofolate to tetrahydrofolate.59
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CHAPTER III
RESULTS AND DISCUSSION
LEISHMANIA GROWTH CURVES WITH AND WITHOUT SULFONAMIDES
The promastigote form of axenic Leishmania tarentolae was grown to the log
phase of the growth curve (day 2) then treated with a 100 µM concentration of three
sulfonamides (Figure 14): N-(2’-methylthiophenyl)-1-napthalne sulfonamide
(Compound A), N-(2’-methoxyphenyl)-1-napthalene sulfonamide (Compound B), and N(2’-methylphenyl)-1-napthalene sulfonamide (Compound C) (provided by Dr. Hamaker).

Figure 14. Chemical structures of N-(2’-methylthiophenyl)-1-napthalene sulfonamide
(Compound A), N-(2’-methoxyphenyl)-1-napthalene sulfonamide (Compound B), and N(2’-methylphenyl)-1-napthalene sulfonamide (Compound C).
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Upon addition to cells grown in BHI, water solubility issues were seen at this
concentration for the three sulfonamides with crystals forming within 24 hours after
addition. Significant inhibitory effects on cell viability were seen with a 100 µM addition
of Compound C, but were not seen with the other two sulfonamides (Figure 15). Within
24-48 hours after addition of Compound C, an 85-95% reduction in cell viability was
observed. Cells transferred to fresh medium were unable to recover over three days,
which was an indication of cell death.

Corrected Average Absorbance as a Function of Incubation
Time with the Addition of 100 µM Sulfonamide
Corrected Average Absorbance at 595 nm

Control Cells

+ 100 µM Compound A

+ 100 µM Compound B

+ 100 µM Compound C
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Time of sulfonamide
addition
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3
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6

Day of Incubation
Figure 15. MTT cell viability results after addition of 100 µM sulfonamides for
representative experiment. One percent DMSO was added to control cells. Values are
the mean ± standard deviation for n = 4 replicates.
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Microscopy was also used to evaluate the cells in the presence of the
sulfonamides. Addition of 100 µM Compound C caused cells to maintain typical shape,
but, per the MTT cell viability assay, lose viability. This is different than typical
senescence phase cell death, which is visually characterized by cells becoming
spherical in shape. This effect on cell shape was noted for each 100 µM Compound C
experiment. Compounds A and B did not negatively affect viability or motility, whereas
cells lost motility in the presence of Compound C. It appeared that Compounds A and B
had a positive effect on the Leishmania, increasing the viability and extending the
culture lifetime relative to control cells.
Because of the water solubility issues with Compound C, it was not possible to
know the effective concentration (EC50) of Compound C that caused negative cell
responses. To determine if lower concentrations could provide similar results 10 µM or
50 µM concentrations of Compound C were added to cell culture and these cells were
evaluated for viability. As seen in Figure 16, lower concentrations of Compound C did
not have the same inhibitory effect without recovery over time. The 10 µM
concentration appeared to have an activating effect on cells, more like that seen for
Compounds A and B. The 50 µM concentration appeared to have some negative effect
on cell viability, but crystal formation was still seen within 24 hours of addition, meaning
the cells were likely not exposed to the full 50 µM concentration. The water solubility
issues also prevented multi-day compound additions.
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Corrected Average Absorbance as a Function of Incubation
Time with the Addition of Compound C
Corrected Average Absorbance at 595 nm
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Figure 16. MTT cell viability of cells with 10 µM, 50 µM, or 100 µM additions of
Compound C. One percent DMSO was added to control cells. Values are the mean ±
standard deviation for n = 4 replicates.

SYNTHESIS OF WATER SOLUBLE STRUCTURAL ANALOGS AND INHIBITION
TESTING
Because insolubility of compounds in water can affect how cells access and
utilize compounds, water solubility can be an important characteristic for therapeutics.
When compounds re-crystalize in the growth medium, the optimal treatment
concentration cannot be easily evaluated and multiple doses cannot be utilized. To
address the water solubility concerns seen with the most inhibitory compound, two
water-soluble analogs of Compound C were synthesized (Figure 17). Because the
group ortho to the amide in Compounds A, B, and C differentiated between cellular
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inhibition, a structural analog of Compound C with a carboxyl group para to the amide
was synthesized (Compound D) and a second compound without the functional group
at the 2’-phenyl position but with a carboxyl para to the amine (Compound E) was also
synthesized and characterized.

Figure 17. Chemical structures of N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene
sulfonamide (Compound D) and N-(4-carboxyl)-1-napthalene sulfonamide (Compound
E).

Compounds D or E were added to cells at 100 µM concentrations and cell
viability was evaluated with an MTT assay. The results in Figure 18 were plotted as a
percentage of control cells (1% DMSO added), and show Compound E had only modest
inhibition of cell viability and was only tested for 2 days after addition, while Compound
D had some inhibitory effect on cell viability at days 1-3 after addition (approximately
70% inhibition) with viability recovery four days after addition. Where results were
compared to Compound C, less inhibition and more apparent cell recovery was
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observed over the 4 days, unlike results with Compound C (approximately 90-96%
inhibition without recovery). However, because Compound D is water soluble, multiple
additions of the compound can be applied to the cells.

Cell Viability as a Percent of Control Cells in the Presence
of Compounds C, D, or E
Cell Viability as a Percent of Control Cells
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E

70%
60%
50%
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20%
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2

3

4

Day of Incubation After Addition

Figure 18. Cell viability as a percent of control cells in the presence of 100 µM
Compound C, D, or E. Values are the mean ± standard deviation for n = 4 replicates.

To determine if inhibitory effects could be accumulative for Compound D, two
sequential doses of 50 µM Compound D were added to cells and evaluated for effect on
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cell viability. As seen in Figure 19, two sequential doses of 50 µM Compound D were
equivalent on day 5 to a single 100 µM addition of Compound D.

Corrected Average Absorbance as a Function of
Incubation Day with the Addition of Compound D
Corrected Average Absorbance at 595 nm
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Figure 19. Representative growth curve showing the impact of two doses of 50 µM
Compound D added on day 3 and day 4 on cell viability compared to single dose of 100
µM Compound D added on day 3. One percent DMSO was added to control cells.
Values are the mean ± standard deviation for n = 4 replicates.

When evaluated by microscopy, the cells treated with Compound D had a
difference appearance than those treated with Compound C. Cells treated with
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Compound C appeared to maintain a typical cell shape but with greatly reduced motility,
though MTT cell viability results indicated cell inhibition. Cells treated with Compound D
presented a cell shape more similar to typical senescence. The visual difference in
cells after treatment implies different pathways of inhibition for these two sulfonamides.

Half maximal effective concentration (EC50) is the concentration of a treatment
that induces a response that is 50% of the maximum response after a specific exposure
time. EC50 was calculated for Compound D by plotting the percent cell viability (percent
of control cells) after 24 hours of exposure as a function of concentration added. As can
be seen in Figure 20, the EC50 was determined to be approximately 74 µM for this study.

Figure 20. Determination of approximate EC50 for Compound D. EC50 was calculated
to be approximately 74 µM.
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EFFECTS OF FOLATE ON CELL VIABILITY WITH AND WITHOUT
SULFONAMIDES

Sulfonamides are known inhibitors of dihydrofolate reductase (DHFR), an
enzyme in the folic acid cycle of bacteria, preventing folate from being reduced to
dihydrofolate and dihydrofolate from being reduced to tetrahydrofolate.7 To determine if
Compounds C or D could be inhibitors of DHFR, 100 µM folic acid and 100 µM
Compound C or D were added to cells in the log phase and evaluated for cell viability
compared to control cells.
As can be seen in Figure 21, addition of an equivalent concentration of folic acid as
Compound C provided approximately 50% more cell viability than cells treated with
Compound C alone. However, cells treated with an equivalent amount of folic acid and
Compound D did not exhibit protection. This also indicates the likelihood of different
pathways of inhibition for these two sulfonamides. A Students two tail statistical t-test,
where p < 0.05 is considered significant, confirmed that mean cell viability as a percent
of the control cells indicated statistically different responses with the addition of
Compound C only or Compound C with 100 µM folic acid. However, there was no
statistical difference with the addition of Compound D only or Compound D with 100 µM
folic acid.50
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Figure 21. Effects of folic acid or folic acid with Compound C or D on cell viability as a
percent of control cells. Values are the mean ± standard deviation for n = 4 replicates.

RECOMBINANT DHFR-TS EXPRESSION AND EVALUATION
To evaluate the effects of the sulfonamide inhibitors on DHFR function,
recombinant DHFR-TS from L. major was expressed, extracted, purified, and activity
evaluated by measuring the rate of NADPH oxidation to NADP+. Using PCR,
recombinant DNA for L. major DHFR-TS was synthesized. Agarose gel electrophoresis
suggested the recombinant DNA contained the proper number of base pairs expected
for the gene. The nucleotide sequence of the DHFR-TS gene, containing 1563
nucleotides, is shown in Figure 22.51
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5’atgtccagggcagctgcgaggtttaagattccgatgccggagacgaaggcagactttgctttcc
cctccctgcgcgccttctccatcgtcgtggccctcgatatgcagcacggcatcggcgacggcga
gtcgatcccgtggcgggtgccggaggacatgacgtttttcaagaaccagacgacgctgctgcgc
aacaagaagccgccgacggagaagaagcgcaacgccgtcgtgatgggccgcaagacttgggaga
gcgtcccggtaaagttccgaccactcaagggacggctgaacatcgtgttatcctcgaaggccac
cgtcgaggagcttctggcgccgctgccggagggacagcgcgcggcggcggcgcaggatgtggtg
gtggtgaacggcggtctggccgaggcgctccgcctcctcgcacgcccgctgtactgcagctcca
tcgagacagcgtattgcgtcggtggtgcgcaggtttacgcggacgccatgctgtcgccgtgcat
cgagaaactgcaggaagtgtacctgacccgcatctacgcgacggcgcctgcgtgtacgcgcttc
tttccgtttccgcccgagaacgcggccacggcgtgggacctggcgtcgtctcagggacgccgca
agagcgaggcggagggcctcgagttcgagatctgcaagtacgtgccgcgcaaccacgaggagcg
gcagtaccttgagctgattgaccgcatcatgaagacggggatcgtgaaggaggaccgcaccggc
gtgggcaccatcagcctcttcggcgcccagatgcgcttctccctacgcgacaaccgcctgccgc
tgctgacgacgaagcgtgtcttctggcgcggcgtgtgcgaggagctgctgtggttcctgcgcgg
ggagacgagtgcgcagctgctggcagacaaggacattcacatctgggacggcaacggttcgcgc
gagtttctcgacagccgcggcttgacagagaataaggagatggacctcggccctgtctacggct
tccagtggcgccacttcggggcagattacaaggggtttgaagcgaactacgacggcgaaggggt
ggaccagatcaagctcatcgtggagaccatcaagacgaacccgaacgaccgccgcctcctagtc
actgcctggaacccgtgcgcgctgcaaaagatggcgctgccgccgtgccacttgcttgctcagt
tctacgtgaacacagacacgagcgagctatcctgcatgttgtaccagcgctcgtgtgacatggg
tcttggcgtccccttcaacattgcctcctacgcgctgctcaccatcctcattgccaaggcgacg
ggtctgcggcctggtgagcttgtgcacaccctcggcgacgcccacgtctaccgcaaccacgttg
atgccctcaaggcgcagctcgagcgagtcccgcacgcgttcccgaccctcatcttcaaggagga
gcggcagtacctcgaggactacgagttgacggacatggaggtgatcgactacgttccacacccg
gcgatcaagatggagatggccgtatag – 3’
Figure 22. Nucleotide sequence for the coding single strand of the L. major DHFR-TS
gene.51

The agarose gel electrophoresis for the digested pET-45b plasmid and the
recombinant DHFR-TS gene are shown in Figure 23. The DNA bands (circled in lanes
2 and 3) were cut from this gel for the pET-45b plasmid (lane 2) and DHFR-TS gene
(lane 3) for ligation.

47

Figure 23. Agarose gel electrophoresis of digested pET-45b and recombinant DHFRTS gene used for ligation. Lane 1 is the standard 1 kb Ladder, lane 2 is the digested
pET-45b plasmid, and lane 3 is the digested recombinant DHFR-TS gene.

After ligation, to ensure the DHFR-TS gene was inserted into the plasmid and
expressed in the dam- dcm- E. coli cells, a BamHI and HindIII digestion was performed
on the purified DNA and an agarose gel was used to evaluate the digested components.
The agarose gel is shown in Figure 24. The gel provided evidence that the gene was
inserted into the pET-45b plasmid and could be transformed into E. coli cells to express
protein.
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Figure 24. Agarose gel electrophoresis of digested plasmid DNA from dam- dcm- E.
coli. Lane 1 is the standard 1 kb ladder and lane 2 is the digested pET-45b plasmid
containing the DHFR-TS gene.

The concentration of the purified DNA, pET-45b with inserted recombinant
DHFR-TS gene was determined using a NanoDrop 2000c Spectrophotometer
(ThermoScientific) by measuring absorbance at 260 nm. The estimated concentration
was found to be 25 ng/µL. Samples of the DNA were sent to the University of Illinois
Urbana-Champaign (UIUC) Core Sequencing Facility in Urbana, IL for DNA sequencing
from the promoter and terminal ends of the DNA for a more accurate output. The data
from UIUC can be seen in Appendix C. Some nucleotides in both sequences could not
be assigned automatically by the software, but manual review of the raw trace allowed
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for some nucleotides to be replaced with the most likely option. An example trace is
shown in Appendix D.

A Basic Local Alignment Search Tool (BLAST) search was performed to identify
regions of similarity between the gene sequencing provided by UIUC and a vast
database of nucleotide sequences from various species.60 It is important to note that
most sequencing methods can become less reliable around 700 nucleotides, so it is
important to evaluate both the promotor and terminal directions of the DNA of interest.
A 96% agreement was identified between nucleotides 190-816 of the sequenced
promoter DHFR-TS gene and the sequence from which the primers were designed,
Sequence ID M12734.1.51 After the terminal sequence of the DHFR-TS gene was
reversed and converted to its complimentary nucleotides, 97% agreement was found
between nucleotides 399-1269 of the sequenced terminal DHFR-TS gene and the
sequence from which the primers were designed.51 However, 395 nucleotides of the
recombinant DHFR-TS gene were inadequately sequenced. Two additional primers
were designed to allow for more accurate sequencing of those nucleotides and data
was, again, acquired from UIUC. The alignments are shown in Appendix E.

The sequenced data were combined, based on the alignment data, and the
nucleotide sequences were translated to amino acids using the translation software
from ExPasy.61 Amino acid alignments were performed between the translated DNA
sequences from the promoter and terminus gene sequences and DHFR-TS from
L. major (M12734)51 using Kalign Multiple Sequence Alignment 62 and BoxShade
software.63 The alignment is shown in Figure 25. There was 100% alignment between
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the amino acid sequences of the L. major DHFR-TS from the Gene Bank and the
recombinant L. major DHFR-TS.

DHFRTS
SeqRecGene

1 MSRAAARFKIPMPETKADFAFPSLRAFSIVVALDMQHGIGDGESIPWRVPEDMTFFKNQT
1 MSRAAARFKIPMPETKADFAFPSLRAFSIVVALDMQHGIGDGESIPWRVPEDMTFFKNQT

DHFRTS
SeqRecGene

61 TLLRNKKPPTEKKRNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGQR
61 TLLRNKKPPTEKKRNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGQR

DHFRTS
SeqRecGene

121 AAAAQDVVVVNGGLAEALRLLARPLYCSSIETAYCVGGAQVYADAMLSPCIEKLQEVYLT
121 AAAAQDVVVVNGGLAEALRLLARPLYCSSIETAYCVGGAQVYADAMLSPCIEKLQEVYLT

DHFRTS
SeqRecGene

181 RIYATAPACTRFFPFPPENAATAWDLASSQGRRKSEAEGLEFEICKYVPRNHEERQYLEL
181 RIYATAPACTRFFPFPPENAATAWDLASSQGRRKSEAEGLEFEICKYVPRNHEERQYLEL

DHFRTS
SeqRecGene

241 IDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGVCEELLWFLRGE
241 IDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGVCEELLWFLRGE

DHFRTS
SeqRecGene

301 TSAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGADYKGFEANYDG
301 TSAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGADYKGFEANYDG

DHFRTS
SeqRecGene

361 EGVDQIKLIVETIKTNPNDRRLLVTAWNPCALQKMALPPCHLLAQFYVNTDTSELSCMLY
361 EGVDQIKLIVETIKTNPNDRRLLVTAWNPCALQKMALPPCHLLAQFYVNTDTSELSCMLY

DHFRTS
SeqRecGene

421 QRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHVDALKAQLERVP
421 QRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHVDALKAQLERVP

DHFRTS
SeqRecGene

481 HAFPTLIFKEERQYLEDYELTDMEVIDYVPHPAIKMEMAV
481 HAFPTLIFKEERQYLEDYELTDMEVIDYVPHPAIKMEMAV

Figure 25. Amino acid alignment of recombinant L. major DHFR-TS gene to DHFR-TS
gene from L. major (Genebank ID: M12734).51 DHFRTS identifies the amino acid
sequence of the L. major gene from the gene bank (M12734) and the SeqRecGene
identifies the amino acid sequence of the combined, sequenced recombinant L. major
amino acid sequence.

Because a crystal structure of the bifunctional enzyme, DHFR-TS, from L. major
does not currently exist, a crystal structure from Trypanosoma cruzi (Protein Data Bank
ID: 3HBB)64 was used instead for identification of amino acids important to the active
site and activity of the enzyme. Figure 26 shows the amino acid comparison of L. major
and T. cruzi, where the amino acids believed to be associated with the active site are
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highlighted in blue (dihydrofolic acid interaction) and red (NADPH interaction). The
DHFR portion of the two enzymes does not align completely, but the active sites within
the enzyme do share common amino acids, making the T. cruzi crystal structure
beneficial in evaluating mutations that may be seen in the sequencing data.

Figure 26. Amino acid alignment of L. major and T. cruzi DHFR-TS. Amino acids
highlighted in blue were identified as binding to dihydrofolic acid and red were identified
as binding to NADPH.
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PROTEIN EXPRESSION, PURIFICATION, AND KINETICS ASSAYS

Once the DHFR-TS gene was inserted into the plasmid, the plasmid was
transformed into competent RILP E. coli cells. The protein was extracted, purified, and
protein concentration was calculated for each fraction using a Bio-Rad Assay.
Calculated protein concentrations are shown in Table 6.

Crude
Supernatant
Column Flow-Through
Buffer Wash
150 mM Imidazole Fractions

Calculated Protein
Concentration
(µg/µL)
3.3-9.8
1.1-8.0
0.5-2.2
0.12-0.21
0.04-0.2

Table 6. Calculated protein concentrations from protein purification.

SDS-PAGE was used to determine if the DHFR-TS protein was expressed in the
E. coli. Aliquots from the lysate (crude extract), supernatant from the crude extract,
column flow through, buffer wash, 10 mM imidazole wash, and 150 mM imidazole
fractions from the cobalt affinity purification process were first evaluated for protein
concentrations using the Bio-Rad assay for protein determination. Based on the results
for this work, the appropriate concentration of each aliquot was prepared and SDSPAGE was used to evaluate protein present, with specific interest in a band appearing
at approximately 60 kD. The molecular weight of DHFR-TS is 58,689 g/mol without the
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His-tag and 59,511 g/mol with the His-tag. A representative gel with expressed protein
at the approximate molecular weight for DHFR-TS is shown in Figure 27.

Figure 27. SDS-PAGE gel of crude lysed cells, column flow through, buffer wash, 10
mM imidazole wash, and 150 mM fractions containing protein. The DHFR-TS enzyme
has a molecular weight of 59,511 g/mol (60 kD) with the His-tag. A band was identified
at approximately 60 kD, indicating DHFR-TS was likely extracted and partially purified.

Because DHFR-TS is soluble and should contain a His-tag, the band shown in
the fractions of 150 mM imidazole were expected to be the protein of interest. Fractions
containing the protein of approximately the correct molecular weight of DHFR-TS were
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evaluated for enzyme kinetic activity. The assay for DHFR activity involved measuring
the absorbance reduction at 340 nm as NADPH was oxidized to NADP+ in the presence
of dihydrofolic acid. For all column fractions obtained in this experiment, enzyme
assays were performed, but no catalytic activity was detected.

One possible reason for lack of enzyme activity could be instability of the DHFRTS bifunctional enzyme. Studies to characterize the bifunctional DHFR-TS of
Trypanosoma brucei, another protozoan parasite, have shown instability of the DHFRTS complex typically caused by the more insoluble TS region of the protein.65 To
improve the stability of the bifunctional enzyme, the authors used an E. coli elongation
factor, Ts, which was designed upstream of the His-tag. The addition of this elongation
factor improved protein stability and allowed for activity of the DHFR and TS portions of
the protein.65 Elongation factors are proteins used in the synthesis of proteins and are
present in large quantities in cells to help elongate peptide chains. Ts is a guaninenucleotide exchange factor that catalyzes mediation of the displacement of a byproduct
of elongation, guanosine diphosphate (GDP), by Tf (a highly abundant elongation
factor). Then guanosine triphosphate (GTP), an energy source necessary for the
peptide bond formation66, is inserted allowing for potential improvement in protein
solubility.

Lack of enzyme activity could also be due to protein misfolding. Chaperonins are
proteins found in all cells that help fold proteins into their proper three-dimensional
structure. GroEL and GroES are E. coli chaperonins that have been well characterized
and studied, and have been found to help fold proteins which is accompanied by the
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hydrolysis of adenosine triphosphate (ATP).67 Chaperonins may work well with many
proteins. However, when E. coli are forced to grow quickly and exhibit high protein
expression, there is more opportunity for misfolding of heterologous proteins. Using a
strain of E. coli that grows at low temperatures can improve the accuracy of folding
activity in the cells. The E. coli strain, ArcticExpress competent cells, improves protein
folding as the cells also express cold-temperature chaperonins Cpn10 and Cpn60.68
Use of ArcticExpress cells can increase the amount of active, soluble protein present,
improving the possibility of enzyme activity.
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CHAPTER IV
CONCLUSIONS AND FUTURE WORK
SULFONAMIDE EFFECTS ON LEISHMANIA PROMASTIGOTE VIABILITY
Promastigote and amastigote forms of Leishmania differ by shape, motility, and
gene expression. The amastigote form of the parasite is commonly found in a
phagocytic cell, such as the macrophage, of the vertebrae host, while the promastigote
form is considered the infective form of the parasite. Targeting the promastigote form of
the life cycle could provide prevention of further infection of phagocytic cells and be an
effective mechanism of treatment for the different forms of leishmaniasis.
In this study, newly synthesized sulfonamides and water-soluble analogs were
evaluated for their inhibitory effects on the growth and viability of Leishmania tarentolae
promastigotes. N-(2’-methylphenyl)-1-napthalene sulfonamide (Compound C) was
seen to inhibit cell viability 90-96% 24 hours after 100 µM addition, though crystallization
was seen in the medium and effective concentration (EC50) was not able to be
determined. Other sulfonamides tested in this experiment, N-(2’-methylthiophenyl)-1napthalene sulfonamide (Compound A) and N-(2’-methoxyphenyl)-1-napthalene
sulfonamide (Compound B), with larger, more electronegative groups ortho to the amine
group, exhibited no negative effect on cell viability or acted as a vitamin to the parasites,
improving cell viability. These data provide insight into the interaction of the
sulfonamide with the inhibitory target (enzyme, transport protein, or other), in that the
small, non-polar functional group ortho to the amine must have some important
interaction that affects function of the target.
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The differences that structural changes have on inhibitory effects could also be
seen with the addition of a carboxyl group para to the amine group. The water-soluble
analog, N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide (Compound D),
exhibited approximately 70% cell viability inhibition after 24 hours with 100 µM addition,
while the water-soluble analog without a methyl group para to the amine group exhibited
only approximately 30% inhibition with one addition of 100 µM. Furthermore,
differences in cell behavior were also documented. Cells treated with 100 µM
Compound C appeared to be paralyzed 24 hours after treatment, as microscopy
indicated cells were without movement but maintained the promastigote cell shape. In
contrast, cells evaluated 24 hours after treatment with 100 µM Compound D appeared
to lose their flagella and were more circular in shape, a cellular change more commonly
associated with cell death; however, both samples of cells were transferred to fresh
medium and little to no cell recovery was noted. This observation leads to the
assumption that there is a difference in inhibitory mechanism between the two
compounds.

Because Compound C was insoluble in the cellular medium at concentrations
from 10 µM to 100 µM, an EC50 value could not be determined. However, the EC50
value for Compound D obtained and compared to those previously reported7 as seen in
Table 7. The EC50 values show that a lower concentration of Compound D, with a
shorter exposure time, is a more effective anti-leishmanial compound compared to other
compounds reported by Peixoto and Beverley.7
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Compound
EC50 after 48 hours
Sulfamoxole
150 µM
Sulfaquinoxaline
600 µM
Dapsone
600 µM
Sulfadimethoxine
>2 mM
Sulfanilamide
>2 mM
Sulfaguanidine
>2 mM
Sulfadiazine
>2 mM
Sulfabenzamide
>2 mM
Sulfamonomethoxine
>2 mM
Sulfamethoxazole
>2 mM
Sulfanitran
>2 mM
Sulfthiazole
>2 mM
Sulfamethizole
>2 mM
Sulfixsoxazole
>2 mM
N -(2'-methylphenyl)-(4-carboxyl)1-napthalene sulfonamide
74 µM*
(Compound D)
Table 7. Comparison of EC50 values for previously published compounds compared to
N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide (Compound D). All EC50
values were reported after 48 hours exposure7, except for Compound D, which was
calculated after 24 hours of exposure (* this thesis).

Peixoto and Beverley also reported that folate addition in the presence of the
sulfonamides tested did not affect inhibition, which was different from the results of
Compound C from this study, but not with Compound D. This, again, enforces the
potential differences in mechanism of inhibition between the two tested compounds and
possibly a different pathway of inhibition between Compound C and the sulfonamides
tested by Peixoto and Beverley.7
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Because Compound D is water-soluble, sequential treatments can be added to
the cells with accumulative inhibition. Experimentation showed that the addition of two
50 µM concentrations of Compound D over 48 hours exhibited equivalent cell viability
inhibition compared to one 100 µM addition 24 hours after exposure. Additive inhibitory
effects could be beneficial as a treatment, allowing lower doses to be given to a patient
to reduce potential side effects and/or manage toxicity to the patient.

Current treatments utilize varying treatment doses that have been shown to
inhibit Leishmania promastigotes. Amphotericin B exhibited 100% inhibition of L.
donovani promastigotes with addition of 0.3 µM69, which was scaled-up to 0.75-1 mg/kg
doses applied daily for 15-20 days for human trials.70 However, at this treatment rate,
side effects can be severe and close monitoring is necessary, leading to increased cost
of therapy. Miltefosine required a 10 µM dose to inhibit 66% of L. donovani
promastigotes after 48 hours.71 In human studies, 50-100 mg doses were required over
28 days for a 94% cure rate, but, it is important to note, that the long half-life makes the
compound vulnerable to drug resistance and the cost and need for monitoring makes
the treatment expensive.70 Antimonial drugs, like glucantime, have been shown to
inhibit L. braziliensis and L. guyanensis in a dose-dependent manner over
concentrations of 0.23-23 mM.72 Human treatments require 20 mg/kg doses over 28-30
days73; however, again, side effects such as cardiotoxicity, renal failure, and
pancreatitis, as well as reduced responsiveness to these treatment types have affected
its use.9 In comparison, N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide
could allow for a novel approach to treatment with potential for reduced parasitic
resistance. As a water-soluble compound, it has the ability to be administered as a
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topical agent, orally, or intravenously, once the pathway and mechanism of inhibition is
more thoroughly evaluated.

DHFR-TS PATHWAY EVALUATION

Agarose gel electrophoresis confirmed that the approximate size of the L. major
DHFR-TS gene was inserted into the pET-45b plasmid. The plasmid was transformed
to competent RILP E. coli and, after protein purification, SDS-PAGE confirmed the
approximate protein size was eluted from the affinity column. However, the DHFR
portion of the enzyme has provided no measurable catalytic activity. The lack of activity
could be due to enzyme instability caused by the more unstable TS portion of the
bifunctional enzyme or by misfolding of the protein within the RILP E. coli used for
protein expression.
Gene sequencing performed at UIUC confirmed the recombinant gene matches
the L. major gene from which the primers were designed near the beginning and end of
the gene sequence, but was not accurately sequenced near the middle of the gene.
Primers were designed and submitted to UIUC for more accurate sequencing of the
gene, as there are 395 nucleotides that were not sequenced. Because the recombinant
gene aligns, it is likely a catalytically active form of the protein could be expressed.

If the gene has been properly expressed, future work should include the
expression of recombinant DHFR-TS in ArcticExpress cells, as growth at lower
temperatures with different chaperonin proteins could improve protein folding. If this is
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not sufficient, it may also be beneficial to encode the Ts elongation factor into new
primers, as this has been seen to improve the solubility of the TS portion of the enzyme.
Expression of the DHFR portion of the bifunctional protein gene alone, without the TS
portion of the enzyme, could also help express the catalytically competent DHFR
enzyme for inhibition testing. The primers for the DHFR gene have been designed, but
the recombinant gene was not successfully expressed without the TS gene. The
method used to successfully ligate the recombinant DHFR-TS gene into pET-45b
plasmid, in which the purified DNA was cut from the agarose gel after electrophoresis,
purified, and used for ligation, should be used for future studies. Understanding the
effect of the inhibitory sulfonamide compounds on DHFR kinetics would be helpful in
identifying pathways of inhibition for the Leishmania promastigotes, as well as better
understanding potential side effects in the host.

FUTURE WORK

Although a significant amount of work has been completed in the evaluation of
sulfonamides synthesized at Illinois State University as inhibitors of Leishmania, there
are still many areas of interest that should be investigated. N-(2’-chlorophenyl)-1napthalene sulfonamide, previously tested by research students in the Jones lab (via
personal communication), showed promising response at low concentrations (76%
inhibition with 15 µM addition, after 24 hours). This compound was not available for
these studies, but it would be very interesting to compare the inhibitory effects of this
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compound with the inhibition demonstrated by Compounds C and D and what effects, if
any, folate would have on the inhibition.

Also, because promastigotes and amastigotes are known to express different
genes, testing the inhibitory effects of Compounds C and D on the amastigote forms of
the Leishmania would help determine if the sulfonamides would inhibit both cellular
forms, which could make for a potentially better treatment. Previous work has shown
axenic amastigotes are acceptable screening methods for anti-leishmanial treatments.5
This method should be used to evaluate Compounds C and D for inhibition of axenic
amastigotes. Testing with Leishmania that infect humans is also essential in insuring
inhibitory effects seen with L. tarentolae are applicable to the human pathogenic
species. The sulfonamides of interest can be sent to collaborators in Colombia to
perform this testing.

The folate pathway also involves other enzymes that could be evaluated in the
presence of the inhibitory sulfonamides, including dihydropteroate synthase and
pteridine reductase (PTR1). Dihydropteroate synthase is reported to be inhibited by
some sulfonamides.31 To test the effects of the sulfonamides on inhibition, the
recombinant genes could be expressed using dam- dcm- competent E. coli and
recombinant protein expressed in either RILP E. coli or ArcticExpress cells. The ability
to inhibit PTR1 could be beneficial in inhibiting the amastigote form of the disease, as
PTR1 has been reported to be more active in acidic environments such as that found in
a phagocytic cell.43 Also, because folate did not have an effect on the inhibitory
performance of Compound D, evaluating the mechanism of inhibition for this compound
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could be interesting. Other pathways of inhibition that may be useful to investigate
include inhibition of carbonic anhydrase74 and disruption of cell proliferation by
disruption of microtubule activity. 33
The promising effects of Compounds C and D for inhibition of L. tarentolae
promastigotes at reasonable treatment concentrations within 24 hours indicates that
these compounds may be good candidates for treatment of human infective species of
Leishmania. Additional work is necessary to understand the true potential of the
compounds of interest, including testing the compounds in the human infective forms of
the parasite, evaluating the compounds’ effects on the amastigote form of Leishmania,
and identifying the pathway and mechanism of inhibition and developing a better
understanding of potential effects in the host. With so many people affected globally,
the need to develop better treatments for leishmaniasis is necessary, and the
compounds in this study could become prospective treatments with additional
investigation.
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APPENDIX A
1H-NMR

OF N-(2’-METHYLPHENYL)-(4-CARBOXYL)-1-NAPTHALENE
SULFONAMIDE (COMPOUND D)
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APPENDIX B
1H-NMR

OF N-(4-CARBOXYL)-1-NAPTHALENE SULFONAMIDE (COMPOUND E)
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APPENDIX C
RAW SEQUENCING DATA FROM UNIVERSITY OF ILLINOIS, URBANA-CHAMPAIGN
(UIUC)
Promoter Primer –
NNNNGNTGNNNNNTNNNNNNTNNNNNGNNNCNNTNGGGNNNNNNNTGNNNNNNNNNNNNNNNNNNNNNNAGGGGGGA
ANTCCTNCACAAAATTTTGTTTACTTAAGAAGGAGATATACCANGGNACATCCCTCTTNAAAGGNCGCTGGGTACCG
GTTCGAATGATGACGACGACTAGAGNNCGGATCCCATGTCCAGGGCAGCTGCGAGGTTTAAGATTCCGATGCCGGAG
ACGAAGGCAGACTTTGCTTTCCCCTCCCTGCGCGCCTTCTCCATCGTCGTGGCCCTCGATATGCAGCACGGCATCGG
CGACGGCGAGTCGATCCCGTGGCGGGTGCCGGAGGACATGACGTTCTTCAAGAACCAGACGACGCTGCTGCGCAACA
AGAAGCCGCCGACGGAGAAGAAGCGCAACGCCGTCGTGATGGGCCGCAAGACTTGGGAGAGCGTCCCGGTAAAGTTC
CGACCACTCAAGGGACNNCTGAACATCGTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGA
GGGACAGCGCGCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGGCGCTCCGCCTCCTCGCAC
GCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTCCGGTGGTGCGCAGGTTTACGCGGACGCCATGCTGTC
GCCGTGCATTCGAGNAAACTGCAAGGAAAGTGTACCTGGACCCGCATCTTACNCCGACGGCNGCCTGCGTNGTACGC
GCCTTCTTTTNCCGTTTTCCCGCCCCGAATAACGGCGGGCCNACGGGCNGNNGGGNACCTTGGNNGNTCGTTCNTCN
ANGGGNANGNCCGCAAANAANNCGAAGGCGGTAAAGGGGNCCCTCCAAAGTTTNCAGAGGAATCTGGNAAAAGNNAC
GGTGGCCNNGNGGNAAANCCNACNAAAGNAAGCCGGGNNAAGTTACCCCTTNAAGNCCNGGAANTNGNNACCCGCCT
CNTCCNATGNAANAAAANCGGGGGGAANTCCGNNGGNAAAAGGGANNGGAACCCNGCTCACCCGGGGGCCNAGNGGG
GGCGACCCCNTTTCANGNCCTNCTNCTTTGNGGGGANNCCCCCGNAAAATGGNNGGCTTTTNNTGNCCCCCCNAANG
GCGCNGAAAAAACACCNCGGCCTTNTGGCCCGCCTTTGNGTTNGNATCNNAAACCAANAAAGCCGNTGTGGTG

Terminal Primer NNNNNNNNNNNNNNNNNNNNNNNNNNNGGCNGTNTTAGCANCGCNGTAGACGAGTCATGTGCTGGCGTTCAAATTTC
GCAGCAGCGGTTTCCTTTANTAGACTCGAGTGCGGCCGCAAGCTTCTATACGGCCATCTCCATCTTGATCGCCGGGT
GTGGAACGTAGTCGATCACCTCCATGTCCGTCAACTCGTAGTCCTCGAGGTACTGCCGCTCCTCCTTGAAGATGAGG
GTCGGGAACGCGTGCGGGACTCGCTCGAGCTGCGCCTTGAGGGCATCAACGTGGTTGCGGTAGACGTGGGCGTCGCC
GAGGGTGTGCACAAGCTCACCAGGCCGCAGACCCGTCGCCTTGGCAATGAGGATGGTGAGCAGCGCGTAGGAGGCAA
TGTTGAAGGGGACGCCAAGACCCATGTCACACGAGCGCTGGTACAACATGCAGGATAGCTCGCTCGTGTCTGTGTTC
ACGTAGAACTGAGCAAGCAAGTGGCACGGCGGCAGCGCCATCTTTTGCAGCGCGCACGGGTTCCAGGCAGTGACTAG
GAGGCGGCGGTCGTTCGGGTTCGTCTTGATGGTCTCCACGATGAGCTTGATCTGGTCCACCCCTTCGCCGTCGTAGT
TCGCTTCAAACCCCTTGTAATCTGCCCCGAAGTGGCGCCACTGGAAGCCGTAGACAGGGCCGAGGTCCATCTCCTTA
TTCTCTGTCAAGCCGCGGCTGTCGAGAAACTCGCGCGAACCGTTGCCGTCCCAGATGTGAATGTCCTTGTCTGCCAG
CAGGNTGCGCACTCGTCTCCCCGCGCAGGAACCACAGNAGCTCCTCGCAACACGCCGNGCCAAGAAAANACGCTTCG
TCGTTCAGCAGCNGCNAGGCGGTTGTCGCGTAAGGGAGAAGCGCATCTTGGGGCGCCNAAAGAGGCTGATGGTGCCC
CACGCCCGGTGCGGTCCCTCCTTNCACGATNCCCGTCTTTCTTNATGCGGTTNAAANCAGCCTCAAGGGTAANTGCC
CGCTNCNNCNNGGGTTGCNCCGGCANCTTANCTTNCAGAATNTTCGAAAATNNAANGCCCCNCCNCCCTCCCTTTTT
TGGGGGGTNCCNTAAAAAAAAACCCNNNGTTCCCNCCCCCNNGTCCNCNTTTTTNCGGGNGGAAAANAGAAAANAAN
AGGGNGTAANNCTAGGTNCCNTNTNGAAANATNCNGGTNNCAGNAANCTTCCNNCNNTTTTNCNAATACCNGGNAAA
AACTGNCNTCCNCNNAAAANCTGNGNAAANCCNAAAAAAAAAACTNTTTTCNGNACTTNNATNCNACNTTCTTTNNA
NAAAANGAAANTNCTGGTANAAACCNTTTTAANAACNAANTTGNTGCTCTCTCACGTNNTTTTCNCCNNGTANGGAT
NANA
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APPENDIX D
EXAMPLE TRACE FILE FROM UIUC
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APPENDIX E
NUCLEOTIDE SEQUENCE ALIGNMENT
DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

1
1
1
1
1

ATGTCCAGGGCAGCTGCGAGGTTTAAGATTCCGATGCCGGAGACGAAGGCAGACTTTGCT
ATGTCCAGGGCAGCTGCGAGGTTTAAGATTCCGATGCCGGAGACGAAGGCAGACTTTGCT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

61
61
1
1
1

TTCCCCTCCCTGCGCGCCTTCTCCATCGTCGTGGCCCTCGATATGCAGCACGGCATCGGC
TTCCCCTCCCTGCGCGCCTTCTCCATCGTCGTGGCCCTCGATATGCAGCACGGCATCGGC
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

121
121
1
1
1

GACGGCGAGTCGATCCCGTGGCGGGTGCCGGAGGACATGACGTTTTTCAAGAACCAGACG
GACGGCGAGTCGATCCCGTGGCGGGTGCCGGAGGACATGACGTTTTTCAAGAACCAGACG
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

181
181
1
1
1

ACGCTGCTGCGCAACAAGAAGCCGCCGACGGAGAAGAAGCGCAACGCCGTCGTGATGGGC
ACGCTGCTGCGCAACAAGAAGCCGCCGACGGAGAAGAAGCGCAACGCCGTCGTGATGGGC
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

241
241
1
1
1

CGCAAGACTTGGGAGAGCGTCCCGGTAAAGTTCCGACCACTCAAGGGACGGCTGAACATC
CGCAAGACTTGGGAGAGCGTCCCGGTAAAGTTCCGACCACTCAAGGGACGGCTGAACATC
----------------------------------------------------------------------------------------------------------CGGGCTGAACATC
------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

301
301
1
14
1

GTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGAGGGACAGCGC
GTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGAGGGACAGCGC
-----------------------------------------------------------GTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGAGGGACAGCGC
------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

361
361
1
74
1

GCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGG-CGCTCCGCCT
GCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGG-CGCTCCGCCT
-------------------TGGTGGTGGTGAACGGCGGTCTGGCCGAGGCTCCTCCACCT
GCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGG-CGCTCCGCCT
------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

420
420
46
134
1

CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC
CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC
CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC
CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC
------------------------------------------------------------

DHFRTS
Pro

479 AGGTTTACGCGGACGCCATGCTGTCGCCGTGCATCGAGAAACTGCAGGAAGTGTACCTGA
480 A-----------------------------------------------------------

77

Mid-Pro
RCMid-Term
RC-Term

105 AGGTTTACGCGGACGCCATGCTGTCGCCGTGCATCGAGAAACTGCAGGAAGTGTACCTGA
193 AGGTTTACGCGGACGCCATGCTGTCGCCGTGCATCGAGAAACTGCAGGAAGTGTACCTGA
1 ------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

539 CCCGCATCTACGCGACGGCGCCTGCGTGTACGCGCTTCTTTCCGTTTCCGCCCGAGAACG
-----------------------------------------------------------165 CCCGCATCTACGCGACGGCGCCTGCATGTACGCGCTTCTTTCCGTTTCCGCCCGAGAACG
253 CCCGCATCTACGCGACGGCGCCTGCGTGTACGCGCTTCTTTCCGTTTCCGCCCGAGAACG
1 ------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

599 CGGCCACGGCGTGGGACCTGGCGTCGTCTCAGGGACGCCGCAAGAGCGAGGCGGAGGGCC
-----------------------------------------------------------225 CGGCCACGGCGTGTGACCTGGCGTCGTCTCAGGGACGCCGCAAGAGCGAGGCGGAGGGCC
313 CGGCCACGGCGTGGGACCTGGCGTCGTCTCAGGGACGCCGCAAGAGCGAGGCGGAGGGCC
1 ------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

659 TCGAGTTCGAGATCTGCAAGTACGTGCCGCGCAACCACGAGGAGCGGCAGTACCTTGAGC
-----------------------------------------------------------285 TCGAGTTCGAGATCTGCAAGTACGTGCCGCGCAACCACGAGGAGCGGCAGTACCTTGAGC
373 TCGAGTTCGAGATCTGCAAGTACGTGCCGCGCAACCACGAGGAGCGGCAGTACCTTGAGC
1 ------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

719 TGATTGACCGCATCATGAAGACGGGGATCGTGAAGGAGGACCGCACCGGCGTGGGCACCA
-----------------------------------------------------------345 TGATTGACCGCATCATGAAGACGGGGATCGTGAAGGAGGACCGCACCGGCGTGGGCACCA
433 TGATTGACCGCATCATGAAGACGGGGATCGTGAAGGAGGACCGCACCGGCGTGGGCACCA
1 ------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

779 TCAGCCTCTTCGGCGCCCAGATGCGCTTCTCCCTACGCGACAACCGCCTGCCGCTGCTGA
-----------------------------------------------------------405 TCAGCCTCTTCGGCGCCCAGATGCGCTTCTCCCTACGCGACAACCGCCTGCCGCTGCTGA
493 TCAGCCTCTTCGGCGCCCAGATGCGCTTCTCCCTACGCGACAACCGCCTGCCGCTGCTGA
1 ------------------------------------------------------------

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

839 CGACGAAGCGTGTCTTCTGGCGCGGCGTGTGCGAGGAGCTGCTGTGGTTCCTGCGCGGG
-----------------------------------------------------------465 CGACCAAGCGTGTCTTCTGGCGCGGCGTGTGCGAGG----------------------553 CGACGAAGCGTGTCTTCTGGCGCGGCGTGTGCGAGGAGCTGCTGTGGTTCCTGCGCGGG
1 ------------------------------------AGCTGCTGTGGTTCCTGCGCGGG

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

898 GAGACGAGTGCGCAGCTGCTGGCAGACAAGGACATTCACATCTGGGACGGCAACGGTTC
----------------------------------------------------------------------------------------------------------------------612 GAGACGAGTGCGCAGCTGCTGGCAGACAAGGACATTCACATGNTGGGANCGGGCA
24 GAGACGAGTGCGCAGCTGCTGGCAGACAAGGACATTCACATCTGGGACGGCAACGGTTC

DHFRTS
Pro
Mid-Pro
RCMid-Term
RC-Term

957 GCGCGAGTTTCTCGACAGCCGCGGCTTGACAGAGAATAAGGAGATGGACCTCGGCCCTGT
----------------------------------------------------------------------------------------------------------------------672 ANCGGTTTCGTC-----------------------------------------------83 GCGCGAGTTTCTCGACAGCCGCGGCTTGACAGAGAATAAGGAGATGGACCTCGGCCCTGT

DHFRTS
1017 CTACGGCTTCCAGTGGCGCCACTTCGGGGCAGATTACAAGGGGTTTGAAGCGAACTACGA
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
143 CTACGGCTTCCAGTGGCGCCACTTCGGGGCAGATTACAAGGGGTTTGAAGCGAACTACGA
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DHFRTS
1077 CGGCGAAGGGGTGGACCAGATCAAGCTCATCGTGGAGACCATCAAGACGAACCCGAACGA
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
203 CGGCGAAGGGGTGGACCAGATCAAGCTCATCGTGGAGACCATCAAGACGAACCCGAACGA
DHFRTS
1137 CCGCCGCCTCCTAGTCACTGCCTGGAACCCGTGCGCGCTGCAAAAGATGGCGCTGCCGCC
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
263 CCGCCGCCTCCTAGTCACTGCCTGGAACCCGTGCGCGCTGCAAAAGATGGCGCTGCCGCC
DHFRTS
1197 GTGCCACTTGCTTGCTCAGTTCTACGTGAACACAGACACGAGCGAGCTATCCTGCATGTT
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
323 GTGCCACTTGCTTGCTCAGTTCTACGTGAACACAGACACGAGCGAGCTATCCTGCATGTT
DHFRTS
1257 GTACCAGCGCTCGTGTGACATGGGTCTTGGCGTCCCCTTCAACATTGCCTCCTACGCGCT
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
383 GTACCAGCGCTCGTGTGACATGGGTCTTGGCGTCCCCTTCAACATTGCCTCCTACGCGCT
DHFRTS
1317 GCTCACCATCCTCATTGCCAAGGCGACGGGTCTGCGGCCTGGTGAGCTTGTGCACACCCT
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
443 GCTCACCATCCTCATTGCCAAGGCGACGGGTCTGCGGCCTGGTGAGCTTGTGCACACCCT
DHFRTS
1377 CGGCGACGCCCACGTCTACCGCAACCACGTTGATGCCCTCAAGGCGCAGCTCGAGCGAGT
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
503 CGGCGACGCCCACGTCTACCGCAACCACGTTGATGCCCTCAAGGCGCAGCTCGAGCGAGT
DHFRTS
1437 CCCGCACGCGTTCCCGACCCTCATCTTCAAGGAGGAGCGGCAGTACCTCGAGGACTACGA
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
563 CCCGCACGCGTTCCCGACCCTCATCTTCAAGGAGGAGCGGCAGTACCTCGAGGACTACGA
DHFRTS
1497 GTTGACGGACATGGAGGTGATCGACTACGTTCCACACCCGGCGATCAAGATGGAGATGGC
Pro
-----------------------------------------------------------Mid-Pro
-----------------------------------------------------------RCMid-Term
-----------------------------------------------------------RC-Term
623 GTTGACGGACATGGAGGTGATCGACTACGTTCCACACCCGGCGATCAAGATGGAGATGGC
DHFRTS
1557 CGTATAGPro
-------Mid-Pro
-------RCMid-Term
-------RC-Term
683 CGTATAG-
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DHFRTS is the L. major gene from the gene data bank, Pro is the sequencing data from
the promoter primer of the recombinant L. major gene, Mid-Pro is the second primer
that was designed to capture the mid-region of the recombinant gene sequence,
RCMid-Term is the reverse compliment of the sequence from the mid-region of the
recombinant gene sequence, and RC-Term is the reverse compliment of the terminal
region of the recombinant gene sequence.
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